Medication Risk Mitigation

Coordinating and Collaborating with Health Care Systems, Universities, and Researchers to Facilitate the Design and Execution of Practice-Based Research
Published:March 01, 2017DOI:https://doi.org/10.1016/j.cger.2017.01.009

      Keywords

      To read this article in full you will need to make a payment
      Purchase one-time access
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.
      Subscribe to Clinics in Geriatric Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Viswanathan M.
        • Kahwati L.C.
        • Golin C.E.
        • et al.
        Medication therapy management interventions in outpatient settings. Comparative effectiveness review No. 138. (Prepared by the RTI International–University of North Carolina at Chapel Hill evidence-based practice center under contract No. 290-2012-00008-I.) AHRQ Publication No. 14(15)-EHC037-EF.
        Agency for Healthcare Research and Quality, Rockville (MD)2014 (Available at:) (Accessed August 10, 2015)
      1. Kohn L.T. Corrigan J.M. Donaldson M.S. To err is human: building a safer health system. National Academy Press, Washington, DC2000
        • McGlynn E.A.
        • Asch S.M.
        • Adams J.
        • et al.
        The quality of health care delivered to adults in the United States.
        N Engl J Med. 2003; 348: 2635-2645
        • Cooper J.A.
        • Cadogan C.A.
        • Patterson S.M.
        • et al.
        Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review.
        BMJ Open. 2015; 5: e009235
        • Marcum Z.A.
        • Amuan M.E.
        • Hanlon J.T.
        • et al.
        Prevalence of unplanned hospitalizations caused by adverse drug reactions in older veterans.
        J Am Geriatr Soc. 2012; 60: 34-41
        • Cahir C.
        • Fahey T.
        • Teeling M.
        • et al.
        Potentially inappropriate prescribing and cost outcomes for older people: a national population study.
        Br J Clin Pharmacol. 2010; 69: 543-552
        • Bradley M.C.
        • Fahey T.
        • Cahir C.
        • et al.
        Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database.
        Eur J Clin Pharmacol. 2012; 68: 1425-1433
        • Hajjar E.R.
        • Hanlon J.T.
        • Artz M.B.
        • et al.
        Adverse drug reaction risk factors in older outpatients.
        Am J Geriatr Pharmacother. 2003; 1: 82-89
        • Maher R.L.
        • Hanlon J.
        • Hajjar E.R.
        Clinical consequences of polypharmacy in elderly.
        Expert Opin Drug Saf. 2014; 13: 57-65
        • Budnitz D.S.
        • Shehab N.
        • Kegler S.R.
        • et al.
        Medication use leading to emergency department visits for adverse drug events in older adults.
        Ann Intern Med. 2007; 147: 755-765
        • Budnitz D.S.
        • Lovegrove M.C.
        • Shehab N.
        • et al.
        Emergency hospitalizations for adverse drug events in older Americans.
        N Engl J Med. 2011; 365: 2002-2012
        • Kongkaew C.
        • Noyce P.R.
        • Ashcroft D.M.
        Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies.
        Ann Pharmacother. 2008; 42: 1017-1025
        • Fulton M.M.
        • Allen E.R.
        Polypharmacy in the elderly: a literature review.
        J Am Acad Nurse Pract. 2005; 17: 123-132
        • Hamilton H.J.
        • Gallagher P.F.
        • O'Mahony D.
        Inappropriate prescribing and adverse drug events in older people.
        BMC Geriatr. 2009; 9: 5
        • Beijer H.J.
        • de Blaey C.J.
        Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies.
        Pharm World Sci. 2002; 24: 46-54
        • Chan M.
        • Nicklason F.
        • Vial J.H.
        Adverse drug events as a cause of hospital admission in the elderly.
        Intern Med J. 2001; 31: 199-205
        • Classen D.C.
        • Pestotnik S.L.
        • Evans R.S.
        • et al.
        Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality.
        JAMA. 1997; 277: 301-306
        • Tangiisuran B.
        • Wright J.
        • Van der Cammen T.
        • et al.
        Adverse drug reactions in elderly: challenges in identification and improving preventative strategies.
        Age Ageing. 2009; 38: 358-359
        • Pretorius R.W.
        • Gataric G.
        • Swedlund S.K.
        • et al.
        Reducing the risk of adverse drug events in older adults.
        Am Fam Physician. 2013; 87: 331-336
        • Bates D.W.
        • Leape L.L.
        • Petrycki S.
        Incidence and preventability of adverse drug events in hospitalized adults.
        J Gen Intern Med. 1993; 8: 289-294
        • Moore J.M.
        • Shartle D.
        • Faudskar L.
        • et al.
        Impact of a patient-centered pharmacy program and intervention in a high-risk group.
        J Manag Care Pharm. 2013; 19: 228-236
      2. Avalere health. Exploring pharmacists' role in a changing healthcare environment. Avalere Health, LLC, Washington, DC2014 (Available at:) (Accessed September 18, 2015)
        • Midwest Pharmacy Research Consortium
        2014 national pharmacist workforce survey.
        University of Minnesota, Minneapolis (MN)2015 (Available at:) (Accessed April 7, 2016)
        • Bluml B.M.
        Definition of medication therapy management: development of professionwide consensus.
        J Am Pharm Assoc (2003). 2005; 45: 566-572
        • American Pharmacists Association and National Association of Chain Drug Stores Foundation
        Medication therapy management in pharmacy practice: core elements of an MTM service model version 2.0.
        American Pharmacists Association, Washington, DC2008 (Available at:) (Accessed September 18, 2015)
        • Ryan R.
        • Santesso N.
        • Lowe D.
        • et al.
        Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.
        Cochrane Database Syst Rev. 2014; (CD007768)
        • Alldred D.P.
        • Raynor D.K.
        • Hughes C.
        • et al.
        Interventions to optimise prescribing for older people in care homes.
        Cochrane Database Syst Rev. 2013; (CD009095)
        • Perlroth D.
        • Marrufo G.
        • Montesinos A.
        • et al.
        Medication therapy management in chronically Ill populations. (Prepared by Acumen, LLC under contract No. HHSM-500-2011-00012I/TOT0.).
        Centers for Medicare & Medicaid Services (CMS), Center for Medicare & Medicaid Innovation, Baltimore (MD)2013 (Available at:) (Accessed September 18, 2015)
        • Academy of Managed Care Pharmacy
        • Shoemaker S.J.
        • Pozniak A.
        • et al.
        Effect of 6 managed care pharmacy tools: a review of the literature.
        J Manag Care Pharm. 2010; 16: S3-S20
        • Holland R.
        • Desborough J.
        • Goodyer L.
        • et al.
        Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis.
        Br J Clin Pharmacol. 2008; 65: 303-316
        • O'Dell K.M.
        • Kucukarslan S.N.
        Impact of the clinical pharmacist on readmission in patients with acute coronary syndrome.
        Ann Pharmacother. 2005; 39: 1423-1427
        • Zillich A.J.
        • Jaynes H.A.
        • Snyder M.E.
        • et al.
        Evaluation of specialized medication packaging combined with medication therapy management: adherence, outcomes, and costs among Medicaid patients.
        Med Care. 2012; 50: 485-493
        • Wittayanukorn S.
        • Westrick S.C.
        • Hansen R.A.
        • et al.
        Evaluation of medication therapy management services for patients with cardiovascular disease in a self-insured employer health plan.
        J Manag Care Pharm. 2013; 19: 385-395
        • Gattis W.A.
        • Hasselblad V.
        • Whellan D.J.
        • et al.
        Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study.
        Arch Intern Med. 1999; 159: 1939-1945
        • Lee A.J.
        • Boro M.S.
        • Knapp K.K.
        • et al.
        Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center.
        Am J Health Syst Pharm. 2002; 59: 2070-2077
        • Isetts B.J.
        • Schondelmeyer S.W.
        • Artz M.B.
        • et al.
        Clinical and economic outcomes of medication therapy management services: the Minnesota experience.
        J Am Pharm Assoc (2003). 2008; 48: 203-211
        • Fox D.
        • Ried L.D.
        • Klein G.E.
        • et al.
        A medication therapy management program's impact on low-density lipoprotein cholesterol goal attainment in Medicare Part D patients with diabetes.
        J Am Pharm Assoc (2003). 2009; 49: 192-199
        • Pindolia V.K.
        • Stebelsky L.
        • Romain T.M.
        • et al.
        Mitigation of medication mishaps via medication therapy management.
        Ann Pharmacother. 2009; 43: 611-620
        • Welch E.K.
        • Delate T.
        • Chester E.A.
        • et al.
        Assessment of the impact of medication therapy management delivered to home-based Medicare beneficiaries.
        Ann Pharmacother. 2009; 43: 603-610
        • Robinson J.D.
        • Segal R.
        • Lopez L.M.
        • et al.
        Impact of a pharmaceutical care intervention on blood pressure control in a chain pharmacy practice.
        Ann Pharmacother. 2010; 44: 88-96
        • Pape G.A.
        • Hunt J.S.
        • Butler K.L.
        • et al.
        Team-based care approach to cholesterol management in diabetes mellitus: two-year cluster randomized controlled trial.
        Arch Intern Med. 2011; 171: 1480-1486
        • Okamoto M.P.
        • Nakahiro R.K.
        Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic.
        Pharmacotherapy. 2001; 21: 1337-1344
        • Isetts B.J.
        • Schondelmeyer S.W.
        • Heaton A.H.
        • et al.
        Effects of collaborative drug therapy management on patients' perceptions of care and health-related quality of life.
        Res Social Adm Pharm. 2006; 2: 129-142
        • Schumock G.T.
        • Butler M.G.
        • Meek P.D.
        • et al.
        Evidence of the economic benefit of clinical pharmacy services: 1996-2000.
        Pharmacotherapy. 2003; 23: 113-132
        • Trygstad T.K.
        • Christensen D.B.
        • Wegner S.E.
        • et al.
        Analysis of the North Carolina long-term care polypharmacy initiative: a multiple-cohort approach using propensity-score matching for both evaluation and targeting.
        Clin Ther. 2009; 31: 2018-2037
        • Viswanathan M.
        • Kahwati L.C.
        • Golin C.E.
        • et al.
        Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis.
        JAMA Intern Med. 2015; 175: 76-87
      3. Centers for Medicare & Medicaid Services. CMS announces Part D Enhanced Medication Therapy Management Model. 2015. Available at: https://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2015-Press-releases-items/2015-09-28.html. Accessed September 29, 2015.

        • Doan J.
        • Zakrzewski-Jakubiak H.
        • Roy J.
        • et al.
        Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy.
        Ann Pharmacother. 2013; 47: 324-332
        • Tannenbaum C.
        • Sheehan N.L.
        Understanding and preventing drug-drug and drug-gene interactions.
        Expert Rev Clin Pharmacol. 2014; 7: 533-544
        • Davies S.J.
        • Eayrs S.
        • Pratt P.
        • et al.
        Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards.
        Br J Clin Pharmacol. 2004; 57: 464-472
        • Zakrzewski-Jakubiak H.
        • Doan J.
        • Lamoureux P.
        • et al.
        Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome p450-based software.
        Am J Geriatr Pharmacother. 2011; 9: 461-470
        • Sweidan M.
        • Reeve J.F.
        • Brien J.A.
        • et al.
        Quality of drug interaction alerts in prescribing and dispensing software.
        Med J Aust. 2009; 190: 251-254
        • Abarca J.
        • Colon L.R.
        • Wang V.S.
        • et al.
        Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies.
        J Manag Care Pharm. 2006; 12: 383-389
        • Tilson H.
        • Hines L.E.
        • McEvoy G.
        • et al.
        Recommendations for selecting drug-drug interactions for clinical decision support.
        Am J Health Syst Pharm. 2016; 73: 576-585
        • Saverno K.R.
        • Hines L.E.
        • Warholak T.L.
        • et al.
        Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions.
        J Am Med Inform Assoc. 2011; 18: 32-37
        • Lapane K.L.
        • Waring M.E.
        • Schneider K.L.
        • et al.
        A mixed method study of the merits of e-prescribing drug alerts in primary care.
        J Gen Intern Med. 2008; 23: 442-446
        • Shah N.R.
        • Seger A.C.
        • Seger D.L.
        • et al.
        Improving acceptance of computerized prescribing alerts in ambulatory care.
        J Am Med Inform Assoc. 2006; 13: 5-11
        • Weingart S.N.
        • Simchowitz B.
        • Shiman L.
        • et al.
        Clinicians' assessments of electronic medication safety alerts in ambulatory care.
        Arch Intern Med. 2009; 169: 1627-1632
        • van der Sijs H.
        • Aarts J.
        • Vulto A.
        • et al.
        Overriding of drug safety alerts in computerized physician order entry.
        J Am Med Inform Assoc. 2006; 13: 138-147
        • Isaac T.
        • Weissman J.S.
        • Davis R.B.
        • et al.
        Overrides of medication alerts in ambulatory care.
        Arch Intern Med. 2009; 169: 305-311
        • Bryant A.D.
        • Fletcher G.S.
        • Payne T.H.
        Drug interaction alert override rates in the Meaningful Use era: no evidence of progress.
        Appl Clin Inform. 2014; 5: 802-813
      4. Roe S, Long R, King K. Pharmacies miss half of dangerous drug combinations. Chicago Tribune. 2016. Available at: http://www.chicagotribune.com/news/watchdog/druginteractions/ct-drug-interactions-pharmacy-met-20161214-story.html. Accessed December 19, 2016.

        • Cavuto N.J.
        • Woosley R.L.
        • Sale M.
        Pharmacies and prevention of potentially fatal drug interactions.
        JAMA. 1996; 275: 1086-1087
        • Dimitrow M.S.
        • Airaksinen M.S.
        • Kivela S.L.
        • et al.
        Comparison of prescribing criteria to evaluate the appropriateness of drug treatment in individuals aged 65 and older: a systematic review.
        J Am Geriatr Soc. 2011; 59: 1521-1530
        • Bulloch M.N.
        • Olin J.L.
        Instruments for evaluating medication use and prescribing in older adults.
        J Am Pharm Assoc (2003). 2014; 54: 530-537
        • Hazlet T.K.
        • Lee T.A.
        • Hansten P.D.
        • et al.
        Performance of community pharmacy drug interaction software.
        J Am Pharm Assoc (Wash). 2001; 41: 200-204
        • Mallet L.
        • Spinewine A.
        • Huang A.
        The challenge of managing drug interactions in elderly people.
        Lancet. 2007; 370: 185-191
        • Hines L.E.
        • Murphy J.E.
        Potentially harmful drug-drug interactions in the elderly: a review.
        Am J Geriatr Pharmacother. 2011; 9: 364-377
        • Page 2nd, R.L.
        • Ruscin J.M.
        The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use.
        Am J Geriatr Pharmacother. 2006; 4: 297-305
        • Laroche M.L.
        • Charmes J.P.
        • Nouaille Y.
        • et al.
        Is inappropriate medication use a major cause of adverse drug reactions in the elderly?.
        Br J Clin Pharmacol. 2007; 63: 177-186
        • Hanlon J.T.
        • Fillenbaum G.G.
        • Kuchibhatla M.
        • et al.
        Impact of inappropriate drug use on mortality and functional status in representative community dwelling elders.
        Med Care. 2002; 40: 166-176
        • Hamilton H.
        • Gallagher P.
        • Ryan C.
        • et al.
        Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients.
        Arch Intern Med. 2011; 171: 1013-1019
        • Bain K.T.
        • Weschules D.J.
        Medication inappropriateness for older adults receiving hospice care: a pilot survey.
        Consult Pharm. 2007; 22: 926-934
        • American Geriatrics Society 2015 Beers Criteria Update Expert Panel
        American geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults.
        J Am Geriatr Soc. 2015; 63: 2227-2246
        • McKibbon K.A.
        • Lokker C.
        • Handler S.M.
        • et al.
        The effectiveness of integrated health information technologies across the phases of medication management: a systematic review of randomized controlled trials.
        J Am Med Inform Assoc. 2012; 19: 22-30
        • Evans W.E.
        • McLeod H.L.
        Pharmacogenomics: drug disposition, drug targets, and side effects.
        N Engl J Med. 2003; 348: 538-549
        • Ferreri S.P.
        • Greco A.J.
        • Michaels N.M.
        • et al.
        Implementation of a pharmacogenomics service in a community pharmacy.
        J Am Pharm Assoc (2003). 2014; 54: 172-180
        • Verbeurgt P.
        • Mamiya T.
        • Oesterheld J.
        How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping.
        Pharmacogenomics. 2014; 15: 655-665
        • Grice G.R.
        • Seaton T.L.
        • Woodland A.M.
        • et al.
        Defining the opportunity for pharmacogenetic intervention in primary care.
        Pharmacogenomics. 2006; 7: 61-65
        • Zanger U.M.
        • Turpeinen M.
        • Klein K.
        • et al.
        Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.
        Anal Bioanal Chem. 2008; 392: 1093-1108
        • Cardelli M.
        • Marchegiani F.
        • Corsonello A.
        • et al.
        A review of pharmacogenetics of adverse drug reactions in elderly people.
        Drug Saf. 2012; 35: 3-20
        • Beier M.T.
        • Panchapagesan M.
        • Carman L.E.
        Pharmacogenetics: has the time come for pharmacists to embrace and implement the science?.
        Consult Pharm. 2013; 28: 696-711
        • Crettol S.
        • de Leon J.
        • Hiemke C.
        • et al.
        Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine.
        Clin Pharmacol Ther. 2014; 95: 254-257
      5. US Food and Drug Administration. Table of pharmacogenomic biomarkers in drug labeling. Available at: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed April 21, 2015.

      6. Schwemm A, Brusig E, Anderegg S, et al. Environmental scan of pharmacogenomics coding: current practice and barriers. Pharmacy Health Information Technology Collaborative. 2015. Available at: http://www.pharmacyhit.org/pdfs/workshop-documents/WG2-Post-2015-01.pdf. Accessed June 22, 2015.

        • O'Donnell P.H.
        • Danahey K.
        • Jacobs M.
        • et al.
        Adoption of a clinical pharmacogenomics implementation program during outpatient care: initial results of the University of Chicago “1,200 Patients Project”.
        Am J Med Genet C Semin Med Genet. 2014; 166C: 68-75
        • Hoffman J.M.
        • Haidar C.E.
        • Wilkinson M.R.
        • et al.
        PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.
        Am J Med Genet C Semin Med Genet. 2014; 166C: 45-55
        • Pulley J.M.
        • Denny J.C.
        • Peterson J.F.
        • et al.
        Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.
        Clin Pharmacol Ther. 2012; 92: 87-95
        • Weitzel K.W.
        • Elsey A.R.
        • Langaee T.Y.
        • et al.
        Clinical pharmacogenetics implementation: approaches, successes, and challenges.
        Am J Med Genet C Semin Med Genet. 2014; 166C: 56-67
        • Owusu-Obeng A.
        • Weitzel K.W.
        • Hatton R.C.
        • et al.
        Emerging roles for pharmacists in clinical implementation of pharmacogenomics.
        Pharmacotherapy. 2014; 34: 1102-1112
        • Johnson J.A.
        • Elsey A.R.
        • Clare-Salzler M.J.
        • et al.
        Institutional profile: university of Florida and Shands hospital personalized medicine program: clinical implementation of pharmacogenetics.
        Pharmacogenomics. 2013; 14: 723-726
        • Shuldiner A.R.
        • Palmer K.
        • Pakyz R.E.
        • et al.
        Implementation of pharmacogenetics: the university of Maryland personalized anti-platelet pharmacogenetics program.
        Am J Med Genet C Semin Med Genet. 2014; 166C: 76-84
        • Bielinski S.J.
        • Olson J.E.
        • Pathak J.
        • et al.
        Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol.
        Mayo Clin Proc. 2014; 89: 25-33
        • Levy K.D.
        • Decker B.S.
        • Carpenter J.S.
        • et al.
        Prerequisites to implementing a pharmacogenomics program in a large health-care system.
        Clin Pharmacol Ther. 2014; 96: 307-309
        • Reiss S.M.
        American Pharmacists Association. Integrating pharmacogenomics into pharmacy practice via medication therapy management.
        J Am Pharm Assoc (2003). 2011; 51: e64-e74
        • Haga S.B.
        • Allen LaPointe N.M.
        • Moaddeb J.
        • et al.
        Pilot study: incorporation of pharmacogenetic testing in medication therapy management services.
        Pharmacogenomics. 2014; 15: 1729-1737
        • Swen J.J.
        • van der Straaten T.
        • Wessels J.A.
        • et al.
        Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19.
        Eur J Clin Pharmacol. 2012; 68: 363-370
        • Moaddeb J.
        • Mills R.
        • Haga S.B.
        Community pharmacists' experience with pharmacogenetic testing.
        J Am Pharm Assoc (2003). 2015; 55: 587-594
        • Crews K.R.
        • Cross S.J.
        • McCormick J.N.
        • et al.
        Development and implementation of a pharmacist-managed clinical pharmacogenetics service.
        Am J Health Syst Pharm. 2011; 68: 143-150
        • Haga S.B.
        • LaPointe N.M.
        • Cho A.
        • et al.
        Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.
        Pharmacogenomics. 2014; 15: 1677-1686
        • Haga S.B.
        • Moaddeb J.
        • Mills R.
        • et al.
        Incorporation of pharmacogenetic testing into medication therapy management.
        Pharmacogenomics. 2015; 16: 1931-1941
        • O'Connor S.K.
        • Ferreri S.P.
        • Michaels N.M.
        • et al.
        Exploratory planning and implementation of a pilot pharmacogenetic program in a community pharmacy.
        Pharmacogenomics. 2012; 13: 955-962
        • Haga S.B.
        • Allen LaPointe N.M.
        • Moaddeb J.
        Challenges to integrating pharmacogenetic testing into medication therapy management.
        J Manag Care Spec Pharm. 2015; 21: 346-352
        • Delafuente J.C.
        Pharmacokinetic and pharmacodynamic alterations in the geriatric patient.
        Consult Pharm. 2008; 23: 324-334
        • Bressler R.
        • Bahl J.J.
        Principles of drug therapy for the elderly patient.
        Mayo Clin Proc. 2003; 78: 1564-1577
        • Relling M.V.
        • Klein T.E.
        CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network.
        Clin Pharmacol Ther. 2011; 89: 464-467
        • Alexander K.M.
        • Divine H.S.
        • Hanna C.R.
        • et al.
        Implementation of personalized medicine services in community pharmacies: perceptions of independent community pharmacists.
        J Am Pharm Assoc (2003). 2014; 54: 510-517
        • Haga S.B.
        • O'Daniel J.M.
        • Tindall G.M.
        • et al.
        Survey of US public attitudes toward pharmacogenetic testing.
        Pharmacogenomics J. 2012; 12: 197-204
        • Latif D.A.
        • McKay A.B.
        Pharmacogenetics and pharmacogenomics instruction in colleges and schools of pharmacy in the United States.
        Am J Pharm Educ. 2005; 69: 152-156
        • Johansen Taber K.A.
        • Dickinson B.D.
        Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties.
        Pharmgenomics Pers Med. 2014; 7: 145-162
        • Suther S.
        • Goodson P.
        Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature.
        Genet Med. 2003; 5: 70-76
        • Mikat-Stevens N.A.
        • Larson I.A.
        • Tarini B.A.
        Primary-care providers' perceived barriers to integration of genetics services: a systematic review of the literature.
        Genet Med. 2015; 17: 169-176
        • Peterson J.F.
        • Field J.R.
        • Shi Y.
        • et al.
        Attitudes of clinicians following large-scale pharmacogenomics implementation.
        Pharmacogenomics J. 2015; 16: 393-398
        • Haga S.B.
        • Tindall G.
        • O'Daniel J.M.
        Professional perspectives about pharmacogenetic testing and managing ancillary findings.
        Genet Test Mol Biomarkers. 2012; 16: 21-24
        • Ferro W.G.
        • Kuo G.M.
        • Jenkins J.F.
        • et al.
        Pharmacist education in the era of genomic medicine.
        J Am Pharm Assoc (2003). 2012; 52: e113-e121
        • McCullough K.B.
        • Formea C.M.
        • Berg K.D.
        • et al.
        Assessment of the pharmacogenomics educational needs of pharmacists.
        Am J Pharm Educ. 2011; 75: 51
        • de Denus S.
        • Letarte N.
        • Hurlimann T.
        • et al.
        An evaluation of pharmacists' expectations towards pharmacogenomics.
        Pharmacogenomics. 2013; 14: 165-175
        • Gottesman O.
        • Kuivaniemi H.
        • Tromp G.
        • et al.
        The electronic medical records and genomics (eMERGE) network: past, present, and future.
        Genet Med. 2013; 15: 761-771
        • Haga S.B.
        • Tindall G.
        • O'Daniel J.M.
        Public perspectives about pharmacogenetic testing and managing ancillary findings.
        Genet Test Mol Biomarkers. 2012; 16: 193-197
        • Houwink E.J.
        • van Luijk S.J.
        • Henneman L.
        • et al.
        Genetic educational needs and the role of genetics in primary care: a focus group study with multiple perspectives.
        BMC Fam Pract. 2011; 12: 5
        • Haga S.B.
        • O'Daniel J.M.
        • Tindall G.M.
        • et al.
        Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions.
        Genet Med. 2011; 13: 723-728
      7. Cogent Research C. Americans skeptical of physicians' knowledge of genomics. Business Wire. 2011. Available at: http://www.businesswire.com/news/home/20110125006349/en/Americans-Skeptical-Physicians%E2%80%99-Knowledge-Genomics. Accessed March 23, 2016.

        • Kirk M.
        • Calzone K.
        • Arimori N.
        • et al.
        Genetics-genomics competencies and nursing regulation.
        J Nurs Scholarsh. 2011; 43: 107-116
        • Murphy J.E.
        • Green J.S.
        • Adams L.A.
        • et al.
        Pharmacogenomics in the curricula of colleges and schools of pharmacy in the United States.
        Am J Pharm Educ. 2010; 74: 7
        • American Society of Health-System Pharmacists
        ASHP statement on the pharmacist's role in clinical Pharmacogenomics.
        Am J Health Syst Pharm. 2015; 72: 579-581
        • Johnson S.G.
        Leading clinical pharmacogenomics implementation: advancing pharmacy practice.
        Am J Health Syst Pharm. 2015; 72: 1324-1328
        • Michaels N.M.
        • Jenkins G.F.
        • Pruss D.L.
        • et al.
        Retrospective analysis of community pharmacists' recommendations in the North Carolina Medicaid medication therapy management program.
        J Am Pharm Assoc (2003). 2010; 50: 347-353
        • DeName B.
        • Divine H.
        • Nicholas A.
        • et al.
        Identification of medication-related problems and health care provider acceptance of pharmacist recommendations in the DiabetesCARE program.
        J Am Pharm Assoc (2003). 2008; 48: 731-736
        • Doucette W.R.
        • McDonough R.P.
        • Klepser D.
        • et al.
        Comprehensive medication therapy management: identifying and resolving drug-related issues in a community pharmacy.
        Clin Ther. 2005; 27: 1104-1111
        • Perera P.N.
        • Guy M.C.
        • Sweaney A.M.
        • et al.
        Evaluation of prescriber responses to pharmacist recommendations communicated by fax in a medication therapy management program (MTMP).
        J Manag Care Pharm. 2011; 17: 345-354